LSR has a long-standing track record of use in the medical industry.

LSR has a long-standing track record of use in the medical industry.

These third-party websites may use their own cookies and tracking devices, log your IP address, and otherwise collect data or solicit your personal information.  Worldwide Locations

a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. As of the date of this proxy statement, all Directors either meet, or are viewed by us as on track to meet, the Guidelines. Named executive officer compensation has either tracked or, in the case of 2022, significantly lagged our performance as compared to adjusted EPS over the Covered Years.

Home // Company // Worldwide Locations // Asia Pacific

Home // Company // Worldwide Locations // EMEA

INVESTMENT IN COMMERCIAL RESOURCES D R I V E S I N N O VAT I V E P R O D U C T P O R T F O L I O AN D S AL E S G R O W T H 19 160 270 2011 2019 2020E 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 0.85 11 12 13 14 15 16 17 18 19 20 21E TARGET NET LEVERAGE BY 2021 ~$1Bn REPURCHASED OVER LAST 10 YEARS ~$350MM PAID OVER LAST 10 YEARS RETURNING VALUE TO SHAREHOLDERS 12 Free Cash Flow Dividends Share Repurchases Deleveraging Strong track record of cash generation put to work in M&A and return to shareholders while modestly levered 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 11 12 13 14 15 16 17 18 19 20 2.9x 2020PF* 2021E Growing Dividend Cumulative Buybacks Net Leverage $ $ p e r s h a re *2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business Cash Generation ~$270MM Another unique value creation lever at Avient is synergy capture with our recent acquisition of Clariant Masterbatch.

Global Compact & fulfilled Communication of Progress (COP) requirements • New Sustainability Strategy overview page including our 2022 AIP ESG metrics • New ESG Performance page with ESG ratings, awards, and certifications • Increased disclosures on carbon emissions, including disclosure of Climate Change Scenario Analysis • Added new Product Stewardship and Chemical Management policies • Enhanced data reporting for Workforce Demographics • Improved social disclosures on human rights, dependent care and special leave and strategic training management 2021 SUSTAINABILITY REPORT Launching integrated sustainability website in parallel with report Aligned with leading reporting frameworks 13 ESG PERFORMANCE & AWARDS 14 16th ENVIRONMENTAL SOCIAL GOVERNANCE 1 (as of 6/30/22) 2022 O U T LO O K $429 $490 $3.05 $3.50 FY 2022 GUIDANCE (TOTAL COMPANY: CURRENT PORTFOLIO) 16 Sales Adjusted Operating Income $4,819 $5,100 + 6% Adjusted EPS + 14% + 15% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 20% excluding FX) 17 CASH FLOW / LEVERAGE ($ millions) 2022E Cash Flow from Operating Activities 400$ Less: Run-Rate CapEx (90) CapEx for Clariant Integration (10) CapEx for IT System Upgrade (15) Total CapEx (115) Free Cash Flow 285$ Adjusted EBITDA 635$ Net Debt / Adjusted EBITDA 1.6x 18 DYNEEMA / DISTRIBUTION UPDATES • Strong performance so far in 2022 in-line with our modeling • Acquisition to be finalized as early as September 1, pending standard regulatory process and closing conditions • Encouraging interest thus far from potential buyers for world-class business with a strong track record • Second round bids due in August DISTRIBUTION 19 PRO FORMA MODELING UPDATE 2022E ($M) Revenue 5,100$ 415$ 5,515$ (1,635)$ 3,880$ Adjusted EBITDA 635 130 765 (109) 656 EBITDA % 12% 31% 14% 7% 17% Adj.

INVESTMENT IN COMMERCIAL RESOURCES D R I V E S I N N O VAT I V E P R O D U C T P O R T F O L I O AN D S AL E S G R O W T H TARGET NET LEVERAGE BY 2021 ~$1Bn REPURCHASED OVER LAST 10 YEARS ~$350MM PAID OVER LAST 10 YEARS RETURNING VALUE TO SHAREHOLDERS 12 Free Cash Flow Dividends Share Repurchases Deleveraging Strong track record of cash generation put to work in M&A and return to shareholders while modestly levered 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 11 12 13 14 15 16 17 18 19 20 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 11 12 13 14 15 16 17 18 19 20 2020PF* 2021E Growing Dividend Cumulative Buybacks Net Leverage $B n $ p r sh ar *2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business Cash Generation 19 160 240 2011 2019 2020E ~$240MM Another unique value creation lever at Avient is synergy capture with our recent acquisition of Clariant Masterbatch.

We harness the collective strength of more than 9,000 employees worldwide to collaborate and build on each other's ideas.